RRA
PBYI icon

Round Rock Advisors’s Puma Biotechnology PBYI Stock Holding History

Round Rock Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$824K Buy
128,912
+23,870
+23% +$154K 0.13% 127
2025
Q4 		$625K Buy
105,042
+39,646
+61% +$211K 0.09% 168
2025
Q3 		$330K Buy
+65,396
New +$277K 0.05% 234

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Round Rock Advisors's PBYI Position: Q1 2026 in Review

Round Rock Advisors increased its Puma Biotechnology (PBYI) stake by 23% in Q1 2026, buying an estimated $154K and bringing the position to 128,912 shares worth $824K. The position accounts for 0.13% of the portfolio, ranked #127.

Round Rock Advisors first reported a position in PBYI in Q3 2025 and has held it in 3 quarters since. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • Round Rock Advisors held 128,912 shares of Puma Biotechnology worth $824K as of Q1 2026.
  • Round Rock Advisors bought 23,870 Puma Biotechnology shares in Q1 2026, an estimated $154K.
  • Puma Biotechnology made up 0.13% of Round Rock Advisors's portfolio in Q1 2026, its #127 holding.
  • Round Rock Advisors first reported a position in Puma Biotechnology in Q3 2025 and has held it in 3 quarters since.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on Round Rock Advisors's 13F filing for Q1 2026, filed 15 May 2026.